With 4.31 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.47 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $16.65 whereas the lowest price it dropped to was $15.0. The 52-week range on SPRY shows that it touched its highest point at $18.90 and its lowest point at $10.00 during that stretch. It currently has a 1-year price target of $31.00. Beta for the stock currently stands at 0.88.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SPRY was down-trending over the past week, with a drop of -12.01%, but this was down by -9.91% over a month. Three-month performance surged to 18.50% while six-month performance rose 36.97%. The stock gained 49.95% in the past year, while it has gained 45.40% so far this year. A look at the trailing 12-month EPS for SPRY yields -0.49 with Next year EPS estimates of -0.77. For the next quarter, that number is -0.44. This implies an EPS growth rate of -1855.83% for this year and 45.36% for next year.
Float and Shares Shorts:
At present, 98.70 million SPRY shares are outstanding with a float of 57.70 million shares on hand for trading. On 2025-07-31, short shares totaled 15.34 million, which was 1561.9999000000003 higher than short shares on 1751241600. In addition to Mr. Richard E. Lowenthal M.B.A., M.S., MSMSEL as the firm’s Co-Founder, President, CEO & Director, Dr. Sarina Tanimoto M.B.A., M.D. serves as its Co-Founder & Chief Medical Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, SPRY reported revenue of $7973000.0 and operating income of -$37177000.0. The EBITDA in the recently reported quarter was -$37177000.0 and diluted EPS was -$0.35.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SPRY since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SPRY analysts setting a high price target of 40.0 and a low target of 25.0, the average target price over the next 12 months is 31.0. Based on these targets, SPRY could surge 152.84% to reach the target high and rise by 58.03% to reach the target low. Reaching the average price target will result in a growth of 95.95% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.18152 being high and -$0.86221 being low. For SPRY, this leads to a yearly average estimate of -$0.658. The surprise factor in the prior quarter was -$0.36. Based on analyst estimates, the high estimate for the next quarter is -$0.13 and the low estimate is -$0.55. The average estimate for the next quarter is thus -$0.32.
